Effect of lecithin-bound iodine on the patients with bronchial asthma.

Abstract

Lecithin-bound iodine (LBI), which has been reported to be a potential candidate for one of the therapeutic modalities for children with bronchial asthma based on the in-vitro study, was also found to be effective in relieving the symptoms of patients with childhood asthma. In addition to the in-vitro effect of downregulation and upregulation of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma), respectively, the clinical effect of LBI was highlighted through the concomitant upregulation of IFN-gamma production by the patients' lymphocytes, which were treated with LBI for 8 weeks. Therefore, LBI may reduce the signs of bronchial asthma by upregulating the synthesis of IFN-gamma that is a representative Th1 cytokine.

• Authors: Yutaka Kawano, Toshiaki Saeki, Takeshi Noma
• Journal: International immunopharmacology (Int Immunopharmacol) Vol. 5 Issue 4 Pg. 805-10 (Apr 2005) ISSN: 1567-5769 [Print] Netherlands
• PMID: 15710348 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Immunologic Factors
• Phosphatidylcholines
• Interleukin-4
• lecithin-bound iodine
• Interferon-gamma
• Iodine

Topics

• Asthma (drug therapy, immunology)
• Child
• Female
• Humans
• Immunologic Factors (pharmacology, therapeutic use)
• Interferon-gamma (biosynthesis)
• Interleukin-4 (biosynthesis)
• Iodine (pharmacology, therapeutic use)
• Lymphocytes (drug effects, immunology)
• Male
• Phosphatidylcholines (pharmacology, therapeutic use)